Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Sitagliptin/Metformin 50/1000 mg in Fed State
NCT05549583Phase 1Completed
- Sponsor
- Galenicum
- Start
- Apr 2018
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sitagliptin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Galenicum. Primary endpoints: Peak Plasma Concentration at 48 hours and Area under the plasma concentration versus time curve 0-t at 48 hours. Started Apr 2018; status: completed.
02
Drugs
sitagliptin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05549583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549583.